Skip Navigation

Lymphoma (follicular non-Hodgkin's) - rituximab

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (review of technology appraisal guidance 37)

Guidance type:  Technology appraisal
Date issued:  February 2008

We will consult on our review plans for this guidance in December 2010.

Reference:  TA137

Summary

This guidance replaces NICE technology appraisal guidance 37 issued in March 2002.

The Institute reviews each piece of guidance it issues. The review and re-appraisal of the use of rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma has resulted in a change in the guidance. In people with relapsed stage III or IV follicular non-Hodgkin's lymphoma, rituximab is now an option in combination with chemotherapy to induce remission or alone as maintenance therapy during remission. Rituximab monotherapy is also an option for people with relapsed or refractory disease when all alternative treatment options have been exhausted.

Top

Documents

For healthcare professionals

For patients, carers and the public

Background information

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

Top

Search NICE guidance


Advanced guidance search

Related guidance

Click the links below to see guidance on similar topics